BofA raised the firm’s price target on AbbVie to $160 from $158 and keeps a Neutral rating on the shares. AbbVie reported a strong Q3 and raised 2024 floor EPS to $11.00, the firm highlights in a research note on Friday. Normally, this would have driven shares higher, but an update in the floor EPS guide was widely anticipated with further uncertainty from the Aesthetics business, BofA adds.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ABBV:
- Early notable gainers among liquid option names on October 30th
- Abbvie Reports Earnings: Did it Beat Estimate Forecasts?
- Piper buyers on AbbVie weakness, raises price target raised to $175
- AbbVie sees FY23 revenue about $54B, consensus $50.51B
- AbbVie sees Q4 adjusted EPS $2.87-$2.91, consensus $2.66